Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02223598
Title A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (CLC-102)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Cleave Biosciences, Inc.

multiple myeloma

hematologic cancer



CB-5083 + Dexamethasone

Age Groups: adult | senior
Covered Countries USA | CAN

No variant requirements are available.